Taysha Gene Therapies (TSHA) Equity Ratio (2022 - 2025)
Historic Equity Ratio for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to 0.69.
- Taysha Gene Therapies' Equity Ratio rose 4040.16% to 0.69 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.69, marking a year-over-year increase of 4040.16%. This contributed to the annual value of 0.45 for FY2024, which is 280.75% up from last year.
- Latest data reveals that Taysha Gene Therapies reported Equity Ratio of 0.69 as of Q3 2025, which was up 4040.16% from 0.75 recorded in Q2 2025.
- Taysha Gene Therapies' Equity Ratio's 5-year high stood at 0.75 during Q2 2025, with a 5-year trough of 0.46 in Q2 2023.
- In the last 4 years, Taysha Gene Therapies' Equity Ratio had a median value of 0.35 in 2024 and averaged 0.26.
- Examining YoY changes over the last 5 years, Taysha Gene Therapies' Equity Ratio showed a top increase of 567272.17% in 2023 and a maximum decrease of 36127.99% in 2023.
- Quarter analysis of 4 years shows Taysha Gene Therapies' Equity Ratio stood at 0.01 in 2022, then surged by 5672.72% to 0.43 in 2023, then increased by 2.81% to 0.45 in 2024, then soared by 55.1% to 0.69 in 2025.
- Its last three reported values are 0.69 in Q3 2025, 0.75 for Q2 2025, and 0.4 during Q1 2025.